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pleted cells and 8 patients were treated at 104 cells/kg/dose and 8
patients received 105 cells/kg/dose. Patients receiving 105 cells/kg/
dose showed signiﬁcantly improved T-cell recovery at 3, 4 and 5
months post-SCT compared with those receiving 104 cells/kg/dose
(P  .05). Accelerated T-cell recovery occurred as a result of
expansion of the effector memory (CD45RACCR-7) population
(P  .05), indicating derivation from the infused allodepleted cells
and that protective T-cell responses are likely to be long-lived.
Using tetramer and ELISPOT assays, we have observed CMV and
EBV-speciﬁc responses in 4/6 evaluable patients at dose level 2 as
early as 2-4 months post-transplant, whereas such responses were
not observed until 6-12 months in dose level 1 patients. The
incidence of signiﬁcant acute (2/16) and chronic GVHD (2/13) was
low. At a median follow-up of 25 months, only 1 patient has died
from infection and 8 of 16 of these high-risk patients are disease-
free. These data demonstrate that allodepleted donor T-cells can
be safely be used to improve T-cell reconstitution after haploiden-
tical SCT and that total cell doses of 3  105/kg are sufﬁcient to
confer useful anti-viral immunity. This approach may broaden the
applicability of haploidentical SCT by reducing infection-associ-
ated mortality (Table 1).
Table 1. Comparison of CD3 ve T-Cell Recovery between Dose
Levels by Month post-SCT
Months
Post-
SCT
Dose
Level 1
(n)
Dose
Level 1
(Median)
Dose
Level 2
(n)
Dose
Level 2
(Median) P Value
1 7 0 6 4 .215
2 7 2 6 20 .216
3* 7* 2* 6* 616* .016*
4* 6* 112* 6* 747* .017*
5* 6* 175* 6* 900* .04*
6 5 488 5 1421 .129
9 3 1047 2 1450 .787
*Signiﬁcant increases in T-cell numbers in dose level 2 compared
to dose level 1.
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PERIPHERAL CD4CD25 REGULATORY T CELLS (Treg) BLOCK ALLO-
REACTIVE HOST ANTI-DONOR T CELLS IN CANINE MIXED HEMATO-
POIETIC CHIMERAS
Lesnikova, M.1, Nikitine, A.1, Pogosov, L.1, Nash, R.A.1,2,
Georges, G.E.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA.
CD4CD25 Treg cells may be important regulators for the
maintenance of immune tolerance after allogeneic hematopoietic
cell transplantation (HCT). In the canine model of nonmyeloab-
lative HCT, stable mixed hematopoietic chimerism persists follow-
ing 2 gray total body irradiation, dog leukocyte antigen (DLA)-
identical HCT and short-term postgrafting immunosuppression
with mycophenolate mofetil and cyclosporine. We hypothesized
that CD4CD25Treg are an important component of the cellular
mechanism maintaining stable mixed chimerism. We asked if de-
pletion of CD4CD25 Treg from peripheral blood mononuclear
cells (PBMC) from dogs with stable mixed chimerism could gen-
erate minor histocompatibility antigen (mHAg)-speciﬁc, host anti-
donor cytotoxic T lymphocytes (CTL). Responder PBMC from 4
mixed chimeric dogs were cultured in MLC with irradiated,
CD34 derived dendritic cells (DC) from the respective DLA-
identical HCT donor. On day 4 of MLC, CD4CD25 T cells
were depleted by either immunomagnetic selection (Miltenyi) us-
ing the CD25 monoclonal antibody (ACT-1) or the addition of
1011 M denileukin diftitox (DAB389IL-2, Ontak). DAB389IL-2 is
a fusion protein of the ADP-ribosyltransferase domain of diphthe-
ria toxin and IL-2. Depletion of CD4CD25bright was 60%-66%
with immunomagnetic selection and 70%-77% with DAB389IL-2.
A secondary MLC was established with CD4CD25 depleted
responder cells and DC from the respective DLA-identical HCT
donor. There was a 54%-95% increase in proliferation of cells
depleted of CD4CD25 T cells with immunomagnetic selection
and a 121%-133% increase in proliferation of DAB389IL-2 treated
cells compared with non-depleted responder cells. We evaluated
mHAg-speciﬁc CTL activity of the CD4CD25 depleted re-
sponder T cells by 51Cr release assay. There was 74%-82% speciﬁc
lysis of the respective HCT donor cells by the CD4CD25
depleted responder T cells, while the non-depleted control re-
sponder cells had 4%-6% speciﬁc lysis. PCR analysis with infor-
mative microsatellite markers conﬁrmed the alloreactive CTL
were of host origin. Depletion of CD4CD25 Treg from PBMC
of mixed chimeras permitted the emergence of host anti-donor
mHAg-speciﬁc CTL. The data suggest (1) mHAg-speciﬁc host
anti-donor T cells persist in stable mixed chimeric dogs, (2) pe-
ripheral CD4CD25 Treg prevent alloreactive immune re-
sponses, (3) mixed hematopoietic chimerism established without T
cell depletion relies on peripheral immune tolerance mechanisms.
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Background: PR1 peptide has been established as a humanmyeloid
leukemia-associated antigen. We studied PR1 peptide vaccine in a
phase I/II clinical trial in HLA-A2 patients with AML, MDS and
CML. There were concerns that prior hematopoietic stem cell trans-
plantation (HSCT)might inhibit an immune response to PR1 vaccine
due to impaired immune reconstitution. To address this question we
studied the outcome in 19 patients who received PR1 vaccine after a
HSCT. Methods: Nineteen patients (AML/MDS 13 and CML 6)
were vaccinated a median of 10 months after one of the following
HSCT: allogeneic related 12, allogeneic unrelated 3, autologous 3,
and syngeneic 1. At the time of vaccination, 7 patients were in CR, 5
had relapsed or refractory CML and 7 had relapsed or refractory
AML. Patients were off systemic immunosuppressive therapy for at
least 2 weeks, and without active acute or chronic GVHD. The
vaccine was given subcutaneously every 3 weeks for a total of 3
injections at one of three dose levels: 0.25, 0.5 and 1.0 mg. Immune
response to the vaccine (IRV) was deﬁned as a doubling of PR1-
speciﬁc cytotoxic T lymphocytes by PR1/HLA-A2 tetramer assay.
Results: After a median follow-up of 23 months, toxicity was limited
to grade I/II injection site reactions, with no exacerbations of acute or
chronic GVHD. PR1-vaccine induced immune responses were ob-
served in 9/18 (50%) evaluable patients. Of the 9 patients with PR1-
speciﬁc immune response, 6 remained in continuous complete remis-
sion (CCR), 2 patients with measurable disease achieved a complete
remission and 1 patient had hematologic improvement. Of the 9
patients without an immune response, 6 had no clinical response/
disease progression, 2 remained in CCR and 1 had hematologic
improvement. There was a signiﬁcant association between the devel-
opment of PR1-speciﬁc immune response and a clinical response (P
.03). Median progression-free survival (PFS) in IRV vs. IRV
patients was 23.4 months vs. 4.1 months, respectively (P  .36). On
univariate and multivariate Cox proportional hazards analysis, mini-
mal residual disease (P  .009) was associated with a lower risk of
progression. Conclusions: PR1 vaccine can produce a PR1-speciﬁc
immune response in patients after HSCT. This immune response is
associated with a better clinical response and a trend towards longer
progression-free survival.
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ACTIVATION OF LMP1- AND LMP2-SPECIFIC T-CELLS FOR THE IMMU-
NOTHERAPY OF EBV POSITIVE MALIGNANCIES WITH AN ADENOVIRAL
VECTOR ENCODING FULL LENGTH LMP1 AND LMP2
Ratnayake, M., Louis, C., Leen, A., Rooney, C.M., Brenner, M.K.,
Heslop, H.E., Gottschalk, S. Center for Cell and Gene Therapy at Baylor
College of Medicine, Houston, TX.
Background: LMP1 and LMP2 are potential targets for the
immunotherapy of EBV-positive malignancies such as nasopharyn-
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